U.S., June 10 -- ClinicalTrials.gov registry received information related to the study (NCT07637162) titled 'Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia' on June 04.
Brief Summary: This is a Phase 3, multi-center, 52-week, open-label trial to evaluate the long-term safety and efficacy of AXS-14 in the management of fibromyalgia.
Study Start Date: April 29
Study Type: INTERVENTIONAL
Condition:
Fibromyalgia
Intervention:
DRUG: AXS-14 (esreboxetine)
AXS-14 tablets taken twice daily.
Recruitment Status: ENROLLING_BY_INVITATION
Sponsor: Axsome Therapeutics, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....